首页 > 最新文献

Pharmacopsychiatry最新文献

英文 中文
Does Lidocaine Shorten Seizure Duration in Electroconvulsive Therapy? 利多卡因在电痉挛治疗中是否缩短癫痫发作时间?
IF 4.3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-09-01 DOI: 10.1055/a-2114-4327
Jose López-Ilundain, Alejandro Ballesteros Prados, Ángela S Rosero Enriquez, Mónica Enguita-Germán, Estefania Uriarte Rosquil, Jose López Gil, Ana Marmol Fábrega, Estitxu Martinez de Zabarte Moraza, Alex R Maughan, Javier Yoldi-Murillo

Background: Electroconvulsive therapy (ECT) is an effective short-term treatment for schizophrenia and depression, amongst other disorders. Lidocaine is typically added to reduce pain from intravenous propofol injection. However, depending on the dose used in the ECT setting, it can shorten seizure duration. The aim of this study was to investigate the effect of lidocaine dose on seizure duration.

Methods: This retrospective, naturalistic cohort study included 169 patients treated with ECT. We examined 4714 ECT sessions with propofol or propofol plus lidocaine. Ictal quality was manually rated by visual inspection. The main outcome of this study was the relation of lidocaine with seizure duration after controlling for socio-demographic, ECT, and other anesthetic variables.

Results: There was a significant negative association between lidocaine usage and seizure duration. Multivariate analyses showed that seizure duration was shortened by an average of 3.21 s in sessions with lidocaine. Moreover, in this subgroup, there was a significant negative dose-dependent association between lidocaine dose and seizure length. Complementarily, a significant positive association between preictal BIS and seizure length was found in the subgroup of sessions where preictal was used.

Conclusions: We provide additional evidence highlighting the importance of caution regarding lidocaine dosing due to the effect on seizure length in the ECT setting. It is advisable for clinicians to exercise caution when administering lidocaine regarding its dosing and seizure length in ECT settings. Future investigation is needed to assess causal relationships by studying certain vulnerable groups or employing other charge calculation techniques, such as the titration method.

背景:电痉挛疗法(ECT)是治疗精神分裂症和抑郁症等疾病的有效短期疗法。利多卡因通常用于减轻静脉注射异丙酚引起的疼痛。然而,根据电痉挛疗法中使用的剂量,它可以缩短癫痫发作的持续时间。本研究旨在探讨利多卡因剂量对癫痫发作持续时间的影响。方法:本回顾性、自然队列研究纳入169例接受电痉挛治疗的患者。我们检查了4714次使用异丙酚或异丙酚加利多卡因的电痉挛治疗。通过目视检查手动评定临界质量。本研究的主要结果是在控制了社会人口统计学、电痉挛疗法和其他麻醉变量后,利多卡因与癫痫发作时间的关系。结果:利多卡因的使用与癫痫发作时间呈显著负相关。多变量分析显示,利多卡因组癫痫发作时间平均缩短3.21秒。此外,在这个亚组中,利多卡因剂量和癫痫发作时间之间存在显著的负剂量依赖关系。与之相辅相成的是,在使用普司妥的亚组中,发现普司妥与BIS和癫痫发作时间之间存在显著的正相关。结论:我们提供了额外的证据,强调了利多卡因剂量的重要性,因为在ECT设置中对癫痫发作时间的影响。建议临床医生在使用利多卡因时谨慎考虑其剂量和癫痫发作时间。未来的研究需要通过研究某些弱势群体或采用其他电荷计算技术(如滴定法)来评估因果关系。
{"title":"Does Lidocaine Shorten Seizure Duration in Electroconvulsive Therapy?","authors":"Jose López-Ilundain,&nbsp;Alejandro Ballesteros Prados,&nbsp;Ángela S Rosero Enriquez,&nbsp;Mónica Enguita-Germán,&nbsp;Estefania Uriarte Rosquil,&nbsp;Jose López Gil,&nbsp;Ana Marmol Fábrega,&nbsp;Estitxu Martinez de Zabarte Moraza,&nbsp;Alex R Maughan,&nbsp;Javier Yoldi-Murillo","doi":"10.1055/a-2114-4327","DOIUrl":"https://doi.org/10.1055/a-2114-4327","url":null,"abstract":"<p><strong>Background: </strong>Electroconvulsive therapy (ECT) is an effective short-term treatment for schizophrenia and depression, amongst other disorders. Lidocaine is typically added to reduce pain from intravenous propofol injection. However, depending on the dose used in the ECT setting, it can shorten seizure duration. The aim of this study was to investigate the effect of lidocaine dose on seizure duration.</p><p><strong>Methods: </strong>This retrospective, naturalistic cohort study included 169 patients treated with ECT. We examined 4714 ECT sessions with propofol or propofol plus lidocaine. Ictal quality was manually rated by visual inspection. The main outcome of this study was the relation of lidocaine with seizure duration after controlling for socio-demographic, ECT, and other anesthetic variables.</p><p><strong>Results: </strong>There was a significant negative association between lidocaine usage and seizure duration. Multivariate analyses showed that seizure duration was shortened by an average of 3.21 s in sessions with lidocaine. Moreover, in this subgroup, there was a significant negative dose-dependent association between lidocaine dose and seizure length. Complementarily, a significant positive association between preictal BIS and seizure length was found in the subgroup of sessions where preictal was used.</p><p><strong>Conclusions: </strong>We provide additional evidence highlighting the importance of caution regarding lidocaine dosing due to the effect on seizure length in the ECT setting. It is advisable for clinicians to exercise caution when administering lidocaine regarding its dosing and seizure length in ECT settings. Future investigation is needed to assess causal relationships by studying certain vulnerable groups or employing other charge calculation techniques, such as the titration method.</p>","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":"56 5","pages":"197-203"},"PeriodicalIF":4.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10197262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Establishing Core Symptoms of Acute Serotonin Reuptake Inhibitor Withdrawal: Results from an International Survey of Online Peer-Support Communities. 建立急性血清素再摄取抑制剂戒断的核心症状:来自在线同伴支持社区的国际调查结果
IF 4.3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-07-01 DOI: 10.1055/a-2078-4593
Bryan Shapiro, Eric Kramer, Dina Khoury, Adrian Preda

Background: Serotonin reuptake inhibitor (SRI) antidepressants are commonly associated with withdrawal reactions. The Discontinuation Emergent Signs and Symptoms (DESS) checklist has been considered the gold standard research and screening tool for SRI withdrawal but has several limitations, including its length, lack of specificity, and omission of baseline symptom and symptom severity scores, making it impractical for use in clinical or research settings. We investigated the prevalence and severity of common SRI withdrawal symptoms to determine whether a very small subset of symptoms can capture most occurrences of SRI withdrawal.

Methods: We surveyed 344 members of online peer-support communities aged 18-65, reporting withdrawal symptoms after chronic SRI treatment. The severity of nine common withdrawal symptoms was evaluated at baseline and during the withdrawal period.

Results: Dizziness, brain zaps, irritability/agitation, and anxiety/nervousness demonstrated the largest increase in severity during withdrawal relative to baseline. Nearly all (97.7%) of the 344 subjects and all (100%) 153 subjects with relatively low baseline symptom scores (total<5) reported a worsening of one of these four symptoms. The presence of a baseline anxiety disorder did not affect rates of withdrawal-emergent anxiety/nervousness.

Conclusion: Nearly all surveyed subjects reported worsening either of dizziness, brain zaps, irritability/agitation, or anxiety/nervousness in acute withdrawal. A screening test incorporating these four core symptoms may be sufficiently sensitive to rule out SRI withdrawal and may be valuable in clinical and research settings. Incorporating withdrawal symptom severity may further enhance specificity.

背景:血清素再摄取抑制剂(SRI)抗抑郁药通常与戒断反应相关。停药紧急体征和症状(DESS)检查表被认为是SRI停药的金标准研究和筛选工具,但有一些局限性,包括其长度,缺乏特异性,遗漏基线症状和症状严重程度评分,使其在临床或研究环境中使用不切实际。我们调查了常见的SRI戒断症状的患病率和严重程度,以确定一小部分症状是否可以捕获大多数SRI戒断症状。方法:我们调查了344名年龄在18-65岁的在线同伴支持社区成员,他们报告了慢性SRI治疗后的戒断症状。在基线和停药期间评估九种常见戒断症状的严重程度。结果:与基线相比,在停药期间,头晕、脑刺激、易怒/躁动和焦虑/紧张的严重程度增加最大。几乎所有(97.7%)344名受试者和所有(100%)153名受试者的基线症状评分相对较低(总)结论:几乎所有被调查的受试者报告急性戒断时头晕、脑刺激、易怒/躁动或焦虑/神经紧张恶化。包含这四种核心症状的筛选试验可能足够敏感,可以排除SRI戒断,并且在临床和研究环境中可能很有价值。纳入戒断症状严重程度可进一步增强特异性。
{"title":"Establishing Core Symptoms of Acute Serotonin Reuptake Inhibitor Withdrawal: Results from an International Survey of Online Peer-Support Communities.","authors":"Bryan Shapiro,&nbsp;Eric Kramer,&nbsp;Dina Khoury,&nbsp;Adrian Preda","doi":"10.1055/a-2078-4593","DOIUrl":"https://doi.org/10.1055/a-2078-4593","url":null,"abstract":"<p><strong>Background: </strong>Serotonin reuptake inhibitor (SRI) antidepressants are commonly associated with withdrawal reactions. The Discontinuation Emergent Signs and Symptoms (DESS) checklist has been considered the gold standard research and screening tool for SRI withdrawal but has several limitations, including its length, lack of specificity, and omission of baseline symptom and symptom severity scores, making it impractical for use in clinical or research settings. We investigated the prevalence and severity of common SRI withdrawal symptoms to determine whether a very small subset of symptoms can capture most occurrences of SRI withdrawal.</p><p><strong>Methods: </strong>We surveyed 344 members of online peer-support communities aged 18-65, reporting withdrawal symptoms after chronic SRI treatment. The severity of nine common withdrawal symptoms was evaluated at baseline and during the withdrawal period.</p><p><strong>Results: </strong>Dizziness, brain zaps, irritability/agitation, and anxiety/nervousness demonstrated the largest increase in severity during withdrawal relative to baseline. Nearly all (97.7%) of the 344 subjects and all (100%) 153 subjects with relatively low baseline symptom scores (total<5) reported a worsening of one of these four symptoms. The presence of a baseline anxiety disorder did not affect rates of withdrawal-emergent anxiety/nervousness.</p><p><strong>Conclusion: </strong>Nearly all surveyed subjects reported worsening either of dizziness, brain zaps, irritability/agitation, or anxiety/nervousness in acute withdrawal. A screening test incorporating these four core symptoms may be sufficiently sensitive to rule out SRI withdrawal and may be valuable in clinical and research settings. Incorporating withdrawal symptom severity may further enhance specificity.</p>","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":"56 4","pages":"133-140"},"PeriodicalIF":4.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9794781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GABAergic Effects of Etifoxine and Alprazolam Assessed by Double Pulse TMS. 双脉冲TMS评价依替辛与阿普唑仑的gaba能作用。
IF 4.3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-07-01 DOI: 10.1055/a-2078-4823
Marco Riebel, Benedikt von Pappenheim, Carolina Kanig, Caroline Nothdurfter, Thomas C Wetter, Rainer Rupprecht, Jens Schwarzbach

Introduction: There is a need for novel anxiolytics with improved side effect profiles compared to benzodiazepines. A promising candidate with alternative pharmacodynamics is the translocator protein ligand, etifoxine.

Methods: To get further insight into its mechanisms of action and side effects compared to the benzodiazepine alprazolam, we performed a double-blind, placebo-controlled, repeated-measures study in 36 healthy male subjects. Participants were examined for trait anxiety and side effects and underwent repeated transcranial magnetic stimulation (TMS) assessments, including motor evoked potentials (MEP), short intracortical inhibition (SICI), intracortical facilitation (ICF), and cortical silent period (CSP).

Results: We observed attenuation of MEPs by alprazolam but not by etifoxine. SICI was not significantly affected by alprazolam or etifoxine. However, the response pattern indicated a lowered SICI threshold after the administration of etifoxine and alprazolam compared to the placebo. ICF and CSP were influenced by neither medication. Alprazolam led to higher sedation and subjective impairment of concentration compared to etifoxine. Individual anxiety trait scores did not affect TMS parameters.

Discussion: This study indicated a favorable side effect profile of etifoxine in healthy volunteers. Moreover, it revealed differential GABA-related effects on neuromuscular function by means of TMS. The side effects and TMS profile of etifoxine are compatible with the involvement of neurosteroidogenesis and a predominant α3 subunit modulation compared to alprazolam.

导论:与苯二氮卓类药物相比,需要一种副作用更好的新型抗焦虑药。具有替代药效学的一个有希望的候选者是转运蛋白配体,etifoxine。方法:为了进一步了解其作用机制和与苯二氮卓类阿普唑仑相比的副作用,我们对36名健康男性受试者进行了双盲、安慰剂对照、重复测量的研究。研究人员检查了参与者的特质焦虑和副作用,并进行了反复的经颅磁刺激(TMS)评估,包括运动诱发电位(MEP)、短皮质内抑制(SICI)、皮质内促进(ICF)和皮质沉默期(CSP)。结果:阿普唑仑对MEPs有抑制作用,而依替辛对MEPs无抑制作用。阿普唑仑或依替辛对SICI无显著影响。然而,反应模式表明,与安慰剂相比,给予依替辛和阿普唑仑后SICI阈值降低。两种药物均不影响ICF和CSP。与依替辛相比,阿普唑仑具有更高的镇静作用和主观浓度损害。个体焦虑特征评分不影响TMS参数。讨论:本研究表明依替辛在健康志愿者中有良好的副作用。此外,经颅磁刺激还揭示了gaba对神经肌肉功能的不同影响。与阿普唑仑相比,etifoxine的副作用和TMS特征与参与神经甾体形成和主要的α3亚基调节相一致。
{"title":"GABAergic Effects of Etifoxine and Alprazolam Assessed by Double Pulse TMS.","authors":"Marco Riebel,&nbsp;Benedikt von Pappenheim,&nbsp;Carolina Kanig,&nbsp;Caroline Nothdurfter,&nbsp;Thomas C Wetter,&nbsp;Rainer Rupprecht,&nbsp;Jens Schwarzbach","doi":"10.1055/a-2078-4823","DOIUrl":"https://doi.org/10.1055/a-2078-4823","url":null,"abstract":"<p><strong>Introduction: </strong>There is a need for novel anxiolytics with improved side effect profiles compared to benzodiazepines. A promising candidate with alternative pharmacodynamics is the translocator protein ligand, etifoxine.</p><p><strong>Methods: </strong>To get further insight into its mechanisms of action and side effects compared to the benzodiazepine alprazolam, we performed a double-blind, placebo-controlled, repeated-measures study in 36 healthy male subjects. Participants were examined for trait anxiety and side effects and underwent repeated transcranial magnetic stimulation (TMS) assessments, including motor evoked potentials (MEP), short intracortical inhibition (SICI), intracortical facilitation (ICF), and cortical silent period (CSP).</p><p><strong>Results: </strong>We observed attenuation of MEPs by alprazolam but not by etifoxine. SICI was not significantly affected by alprazolam or etifoxine. However, the response pattern indicated a lowered SICI threshold after the administration of etifoxine and alprazolam compared to the placebo. ICF and CSP were influenced by neither medication. Alprazolam led to higher sedation and subjective impairment of concentration compared to etifoxine. Individual anxiety trait scores did not affect TMS parameters.</p><p><strong>Discussion: </strong>This study indicated a favorable side effect profile of etifoxine in healthy volunteers. Moreover, it revealed differential GABA-related effects on neuromuscular function by means of TMS. The side effects and TMS profile of etifoxine are compatible with the involvement of neurosteroidogenesis and a predominant α3 subunit modulation compared to alprazolam.</p>","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":"56 4","pages":"154-161"},"PeriodicalIF":4.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10152800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Effects of Anesthesia Changes During Maintenance ECT: A Longitudinal Comparison of Seizure Quality Under Anesthesia Using Propofol/Esketamine Versus Methohexital. 维持电痉挛期间麻醉改变的影响:异丙酚/艾氯胺酮与甲氧己酮麻醉下癫痫发作质量的纵向比较。
IF 4.3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-07-01 DOI: 10.1055/a-2058-9010
Isabel Methfessel, David Zilles-Wegner, Nils Kunze-Szikszay, Michael Belz

Introduction: The effectiveness of ECT relies on the induction of a generalized cerebral seizure. Among others, seizure quality (SQ) is potentially influenced by the anesthetic drug used. Commonly used anesthetics comprise barbiturates, etomidate, propofol, and esketamine, with different characteristics and impacts on seizure parameters. So far, no studies have compared the influence of methohexital vs. a combination of propofol/esketamine on established SQ parameters.

Methods: This retrospective longitudinal study compared eight established SQ parameters (PSI, ASEI, MSC, midictal amplitude, motor and electroencephalography (EEG) seizure duration, concordance, PHR) before and after the change from propofol/esketamine to methohexital in 34 patients under maintenance ECT. Each patient contributed four measurements, two before and two after the anesthesia change. Anesthesia dose, stimulus dose, electrode placement, and concomitant medication remained unchanged throughout the analyzed treatments.

Results: Under methohexital (M=88.97 mg), ASEI (p=0.039 to 0.013) and midictal amplitude (p=0.022 to<0.001) were significantly lower, whereas seizure duration (motor and EEG) was significantly longer when compared to propofol/esketamine (M=64.26 mg/51.18 mg; p=0.012 to<0.001). PSI, MSC, seizure concordance, and PHR were not affected by the anesthetic used.

Discussion: Although to what extent these parameters correlate with the therapeutic effectiveness remains ambiguous, a decision for or against a particular anesthetic could be considered if a specific SQ parameter needs optimization. However, no general superiority for one specific substance or combination was found in this study. In the next step, anesthetic effects on treatment response and tolerability should be focused on.

引言:ECT的有效性依赖于全身性大脑发作的诱导。其中,癫痫发作质量(SQ)可能受到所用麻醉药物的影响。常用的麻醉药包括巴比妥类、依托咪酯、异丙酚和艾氯胺酮,它们具有不同的特性和对癫痫发作参数的影响。到目前为止,还没有研究比较甲氧己酮与异丙酚/艾氯胺酮联合使用对既定SQ参数的影响。方法:本回顾性纵向研究比较了34例维持性ECT患者从异丙酚/艾氯胺酮到甲氧己酮转换前后的8个SQ参数(PSI、ASEI、MSC、中间振幅、运动和脑电图(EEG)癫痫发作时间、一致性、PHR)。每位患者进行了四次测量,两次在麻醉改变前,两次在麻醉改变后。麻醉剂量、刺激剂量、电极放置和伴随用药在整个分析治疗过程中保持不变。结果:在甲氧六酮(M=88.97 mg)、ASEI (p=0.039 ~ 0.013)和中间振幅(p=0.022 ~ 0.012)下,尽管这些参数与治疗效果的相关性尚不明确,但如果特定SQ参数需要优化,则可以考虑决定是否使用特定麻醉剂。然而,在这项研究中没有发现一种特定物质或组合的普遍优势。下一步,应重点研究麻醉对治疗反应和耐受性的影响。
{"title":"Effects of Anesthesia Changes During Maintenance ECT: A Longitudinal Comparison of Seizure Quality Under Anesthesia Using Propofol/Esketamine Versus Methohexital.","authors":"Isabel Methfessel,&nbsp;David Zilles-Wegner,&nbsp;Nils Kunze-Szikszay,&nbsp;Michael Belz","doi":"10.1055/a-2058-9010","DOIUrl":"https://doi.org/10.1055/a-2058-9010","url":null,"abstract":"<p><strong>Introduction: </strong>The effectiveness of ECT relies on the induction of a generalized cerebral seizure. Among others, seizure quality (SQ) is potentially influenced by the anesthetic drug used. Commonly used anesthetics comprise barbiturates, etomidate, propofol, and esketamine, with different characteristics and impacts on seizure parameters. So far, no studies have compared the influence of methohexital vs. a combination of propofol/esketamine on established SQ parameters.</p><p><strong>Methods: </strong>This retrospective longitudinal study compared eight established SQ parameters (PSI, ASEI, MSC, midictal amplitude, motor and electroencephalography (EEG) seizure duration, concordance, PHR) before and after the change from propofol/esketamine to methohexital in 34 patients under maintenance ECT. Each patient contributed four measurements, two before and two after the anesthesia change. Anesthesia dose, stimulus dose, electrode placement, and concomitant medication remained unchanged throughout the analyzed treatments.</p><p><strong>Results: </strong>Under methohexital (<i>M</i>=88.97 mg), ASEI (<i>p</i>=0.039 to 0.013) and midictal amplitude (<i>p</i>=0.022 to<0.001) were significantly lower, whereas seizure duration (motor and EEG) was significantly longer when compared to propofol/esketamine (M=64.26 mg/51.18 mg; <i>p</i>=0.012 to<0.001). PSI, MSC, seizure concordance, and PHR were not affected by the anesthetic used.</p><p><strong>Discussion: </strong>Although to what extent these parameters correlate with the therapeutic effectiveness remains ambiguous, a decision for or against a particular anesthetic could be considered if a specific SQ parameter needs optimization. However, no general superiority for one specific substance or combination was found in this study. In the next step, anesthetic effects on treatment response and tolerability should be focused on.</p>","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":"56 4","pages":"141-148"},"PeriodicalIF":4.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9789236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High Prescribing and State-Level Variation in Z-Drug Use Among Medicare Patients. 医疗保险患者z -药物使用的高处方和州水平差异。
IF 2.2 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-07-01 Epub Date: 2023-06-07 DOI: 10.1055/a-2085-2299
Kaitlin E Anderson, Rachel I Gifeisman, James L Basting, Donovan J Harris, Antonica R Rajan, Kenneth L McCall, Brian J Piper

Background: Z-drugs are nonbenzodiazepine hypnotics used for sleep initiation and maintenance; these drugs increase the risk of fall-related injuries in older adults. The American Geriatrics Society's Beers criteria classifies Z-drugs as high-risk and strongly recommends avoiding prescribing Z-drugs to older adults due to adverse effects. The study objectives were to determine the prevalence of Z-drug prescribing among Medicare Part D patients and identify state or specialty-dependent prescribing differences. This study also aimed to determine prescribing patterns of Z-drugs to Medicare patients.

Methods: Z-drug prescription data was extracted from the Centers for Medicare and Medicaid Services State Drug Utilization Data for 2018. For all 50 states, the number of prescriptions per 100 Medicare enrollees and days-supply per prescription was determined. The percentage of total prescriptions prescribed by each specialty and the average number of prescriptions per provider within each specialty was also determined.

Results: Zolpidem was the most prescribed Z-drug (95.0%). Prescriptions per 100 enrollees were significantly high in Utah (28.2) and Arkansas (26.7) and significantly low in Hawaii (9.3) relative to the national average (17.5). Family medicine (32.1%), internal medicine (31.4%), and psychiatry (11.7%) made up the largest percentages of total prescriptions. The number of prescriptions per provider was significantly high among psychiatrists.

Discussion: Contrary to the Beers criteria, Z-drugs are prescribed to older adults at high rates.

背景:z类药物是用于睡眠启动和维持的非苯二氮卓类催眠药物;这些药物增加了老年人跌倒相关损伤的风险。美国老年病学会的比尔斯标准将z -药物归类为高风险药物,并强烈建议避免给老年人开z -药物的处方,因为它会产生副作用。研究目的是确定z -药物处方在医疗保险D部分患者中的流行程度,并确定州或专科处方差异。本研究还旨在确定z -药物对医保患者的处方模式。方法:从2018年医疗保险和医疗补助服务中心的国家药物利用数据中提取z -药物处方数据。对于所有50个州,每100名医疗保险参保者的处方数量和每个处方的天数都是确定的。还确定了每个专科开出的总处方的百分比和每个专科内每个提供者的平均处方数。结果:唑吡坦是处方最多的z型药物(95.0%)。与全国平均水平(17.5)相比,犹他州(28.2)和阿肯色州(26.7)的每100名参选者的处方数量明显较高,而夏威夷(9.3)的处方数量明显较低。家庭医学(32.1%)、内科(31.4%)和精神病学(11.7%)占总处方的比例最大。在精神科医生中,每个医生的处方数量明显很高。讨论:与比尔斯的标准相反,z型药物被开给老年人的比例很高。
{"title":"High Prescribing and State-Level Variation in Z-Drug Use Among Medicare Patients.","authors":"Kaitlin E Anderson, Rachel I Gifeisman, James L Basting, Donovan J Harris, Antonica R Rajan, Kenneth L McCall, Brian J Piper","doi":"10.1055/a-2085-2299","DOIUrl":"10.1055/a-2085-2299","url":null,"abstract":"<p><strong>Background: </strong>Z-drugs are nonbenzodiazepine hypnotics used for sleep initiation and maintenance; these drugs increase the risk of fall-related injuries in older adults. The American Geriatrics Society's Beers criteria classifies Z-drugs as high-risk and strongly recommends avoiding prescribing Z-drugs to older adults due to adverse effects. The study objectives were to determine the prevalence of Z-drug prescribing among Medicare Part D patients and identify state or specialty-dependent prescribing differences. This study also aimed to determine prescribing patterns of Z-drugs to Medicare patients.</p><p><strong>Methods: </strong>Z-drug prescription data was extracted from the Centers for Medicare and Medicaid Services State Drug Utilization Data for 2018. For all 50 states, the number of prescriptions per 100 Medicare enrollees and days-supply per prescription was determined. The percentage of total prescriptions prescribed by each specialty and the average number of prescriptions per provider within each specialty was also determined.</p><p><strong>Results: </strong>Zolpidem was the most prescribed Z-drug (95.0%). Prescriptions per 100 enrollees were significantly high in Utah (28.2) and Arkansas (26.7) and significantly low in Hawaii (9.3) relative to the national average (17.5). Family medicine (32.1%), internal medicine (31.4%), and psychiatry (11.7%) made up the largest percentages of total prescriptions. The number of prescriptions per provider was significantly high among psychiatrists.</p><p><strong>Discussion: </strong>Contrary to the Beers criteria, Z-drugs are prescribed to older adults at high rates.</p>","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":"56 4","pages":"149-153"},"PeriodicalIF":2.2,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9963277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Revisiting the World's Strictest COVID-19 Lockdown: Formidable Mental Health Challenges. 重温世界上最严格的COVID-19封锁:艰巨的心理健康挑战。
IF 4.3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-07-01 DOI: 10.1055/a-2108-2164
Beier Guan, Ruihua Li, Chuanning Huang, Jiang Du, Min Zhao, Shuyan Liu

Introduction: Many nations have implemented lockdowns to prevent and minimize the spread of infections in healthcare settings. However, the impact of lockdown duration on mental health remains controversial.

Methods: We conducted a retrospective study using online questionnaires to assess the mental health status of the general population during the Shanghai lockdown period from March to May 2022. The mental health of the participants was evaluated by the 12-item General Health Questionnaire (GHQ-12), in which a cut-off score of 12 or more indicated psychological distress. A logistic regression model was used to evaluate the relationship between lockdown duration and mental health.

Results: Among 2139 participants (mean age: 26.12 years, standard deviation: 6.37, 731 females; 1378 unmarried; 1099 Shanghai residents), approximately 47% reported psychological distress (GHQ-12≥12). Participants exposed to lockdown reported significantly higher GHQ-12 scores (11.93±6.81 vs. 8.73±6.35, p<0.001). In our logistic regression model, participants who experienced the longest lockdown (43-61 days) had a significantly higher risk of psychological distress compared with those who did not (odds ratio: 3.10, 95% confidence interval: 2.06-4.70, p<0.001).

Discussion: Lockdown duration significantly affects mental health, with longer lockdown duration being associated with worse mental health status. The relationship between lockdown and mental health should not be neglected in case of lockdown in response to future pandemics.

导言:许多国家已经实施了封锁,以预防和尽量减少感染在医疗机构中的传播。然而,封锁时间对心理健康的影响仍然存在争议。方法:采用在线问卷调查的方法,对2022年3月至5月上海封城期间普通人群的心理健康状况进行回顾性研究。参与者的心理健康状况通过12项一般健康问卷(GHQ-12)进行评估,其中截止得分为12分或更高表示心理困扰。使用逻辑回归模型评估封锁时间与心理健康之间的关系。结果:在2139名参与者中(平均年龄:26.12岁,标准差:6.37),女性731名;1378年未婚;1099名上海居民),约47%报告心理困扰(GHQ-12≥12)。暴露于封城的参与者报告的GHQ-12得分显著较高(11.93±6.81比8.73±6.35)。讨论:封城持续时间显著影响心理健康,封城持续时间越长,心理健康状况越差。如果为应对未来的流行病而采取封锁措施,不应忽视封锁与心理健康之间的关系。
{"title":"Revisiting the World's Strictest COVID-19 Lockdown: Formidable Mental Health Challenges.","authors":"Beier Guan,&nbsp;Ruihua Li,&nbsp;Chuanning Huang,&nbsp;Jiang Du,&nbsp;Min Zhao,&nbsp;Shuyan Liu","doi":"10.1055/a-2108-2164","DOIUrl":"https://doi.org/10.1055/a-2108-2164","url":null,"abstract":"<p><strong>Introduction: </strong>Many nations have implemented lockdowns to prevent and minimize the spread of infections in healthcare settings. However, the impact of lockdown duration on mental health remains controversial.</p><p><strong>Methods: </strong>We conducted a retrospective study using online questionnaires to assess the mental health status of the general population during the Shanghai lockdown period from March to May 2022. The mental health of the participants was evaluated by the 12-item General Health Questionnaire (GHQ-12), in which a cut-off score of 12 or more indicated psychological distress. A logistic regression model was used to evaluate the relationship between lockdown duration and mental health.</p><p><strong>Results: </strong>Among 2139 participants (mean age: 26.12 years, standard deviation: 6.37, 731 females; 1378 unmarried; 1099 Shanghai residents), approximately 47% reported psychological distress (GHQ-12≥12). Participants exposed to lockdown reported significantly higher GHQ-12 scores (11.93±6.81 vs. 8.73±6.35, <i>p</i><0.001). In our logistic regression model, participants who experienced the longest lockdown (43-61 days) had a significantly higher risk of psychological distress compared with those who did not (odds ratio: 3.10, 95% confidence interval: 2.06-4.70, <i>p</i><0.001).</p><p><strong>Discussion: </strong>Lockdown duration significantly affects mental health, with longer lockdown duration being associated with worse mental health status. The relationship between lockdown and mental health should not be neglected in case of lockdown in response to future pandemics.</p>","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":"56 4","pages":"162-164"},"PeriodicalIF":4.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9816035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Role of Circadian Rhythmicity and CLOCK Genes in Psychiatry. 昼夜节律和 CLOCK 基因在精神病学中的作用。
IF 4.3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-05-01 Epub Date: 2023-05-15 DOI: 10.1055/a-2078-4905
Denise Palm, Johannes Thome

Circadian rhythms are biological oscillations, that perpetuate themselves even in the absence of "zeitgebers" (external time cues), with a period of approximately 24 hours. The master pacemaker is the suprachiasmatic nucleus (SCN) of the hypothalamus. The SCN is entrained by environmental factors, particularly light, to the 24-hour light-dark cycle by the Earth's rotation. Peripheral circadian oscillators, located in multiple cell types and tissues, are controlled by signals arising from the SCN and from the environment, particularly food intake, hormonal signals and body-temperature fluctuations. Circadian rhythmicity is observable in almost every cell of living organisms including humans and, for example in cell cultures, these rhythms persist even without the SCN 1 2.

昼夜节律是一种生物振荡,即使在没有 "zeitgebers"(外部时间线索)的情况下也会持续,周期约为 24 小时。下丘脑上核(SCN)是昼夜节律的主起搏器。下丘脑上核(SCN)受环境因素(尤其是光线)的影响,按照地球自转的 24 小时光暗周期进行调节。位于多种细胞类型和组织中的外周昼夜节律振荡器受控于来自 SCN 和环境的信号,特别是食物摄入量、激素信号和体温波动。昼夜节律在包括人类在内的几乎所有生物细胞中都能观察到,例如在细胞培养中,即使没有昼夜节律核,这些节律也会持续存在1 2。
{"title":"The Role of Circadian Rhythmicity and CLOCK Genes in Psychiatry.","authors":"Denise Palm, Johannes Thome","doi":"10.1055/a-2078-4905","DOIUrl":"10.1055/a-2078-4905","url":null,"abstract":"<p><p>Circadian rhythms are biological oscillations, that perpetuate themselves even in the absence of \"zeitgebers\" (external time cues), with a period of approximately 24 hours. The master pacemaker is the suprachiasmatic nucleus (SCN) of the hypothalamus. The SCN is entrained by environmental factors, particularly light, to the 24-hour light-dark cycle by the Earth's rotation. Peripheral circadian oscillators, located in multiple cell types and tissues, are controlled by signals arising from the SCN and from the environment, particularly food intake, hormonal signals and body-temperature fluctuations. Circadian rhythmicity is observable in almost every cell of living organisms including humans and, for example in cell cultures, these rhythms persist even without the SCN 1 2.</p>","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":"56 3","pages":"85-86"},"PeriodicalIF":4.3,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9515596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
„AGNP-Preis für Forschung in der Psychopharmakologie“ in Höhe von 5.000 €. “AGNP-Preis研发Psychopharmakologie”相当于5000€.
IF 4.3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-05-01 DOI: 10.1055/a-2079-9272
Wohl kaum eine andere Arzneimittelgruppe hat durch ihre Einführung so immense therapeutische Möglichkeiten eröffnet wie die Psychopharmaka. In den über 60 Jahren seit ihrer Entdeckung haben sie vielen psychisch Kranken entscheidend geholfen. Heute sind sie aus der Therapie psychischer Erkrankungen nicht mehr wegzudenken.
{"title":"„AGNP-Preis für Forschung in der Psychopharmakologie“ in Höhe von 5.000 €.","authors":"","doi":"10.1055/a-2079-9272","DOIUrl":"https://doi.org/10.1055/a-2079-9272","url":null,"abstract":"Wohl kaum eine andere Arzneimittelgruppe hat durch ihre Einführung so immense therapeutische Möglichkeiten eröffnet wie die Psychopharmaka. In den über 60 Jahren seit ihrer Entdeckung haben sie vielen psychisch Kranken entscheidend geholfen. Heute sind sie aus der Therapie psychischer Erkrankungen nicht mehr wegzudenken.","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":"56 3","pages":"126"},"PeriodicalIF":4.3,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9476736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Role of Mood Stabilizers in Children and Adolescents with Anorexia Nervosa: A 1-year Follow-Up, Propensity Score-Matched Study. 情绪稳定剂在儿童和青少年神经性厌食症中的作用:1年随访,倾向评分匹配研究。
IF 4.3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-05-01 DOI: 10.1055/a-2018-4946
Jacopo Pruccoli, Antonia Parmeggiani

Background: The existing literature on the use of mood stabilizers (MS) in children and adolescents with anorexia nervosa (AN) is limited, for the most part, to small case studies.

Methods: This was an observational, naturalistic, propensity score-matched study. Subjects treated and not-treated with MS were compared by being matched via propensity score on age, sex, concurrent atypical antipsychotics, and concurrent antidepressants. General and AN-specific psychopathology was assessed with Symptom Check List-90-R, Beck Depression Inventory-II, Eating Disorders Inventory-3, and Body Uneasiness Test-A. Potential differences in admission-discharge modifications (body mass index (BMI), psychopathology) among the two groups were assessed. Finally, re-hospitalizations after 1-year follow-up were assessed with Kaplan-Meier analyses.

Results: The study enrolled 234 hospitalized patients (15.9+/-3.3 years; 26, 11.1% receiving MS). After propensity-score matching, 26 MS patients matched with 26 MS-not-treated subjects were included. MS were used for a mean of 126.1 (+/-87.3) days, and two cases of side effects were documented (alopecia and somnolence with valproate). No significant difference between MS-treated and not-treated patients emerged concerning admission-discharge improvements in BMI and AN-specific or general psychopathology. The cumulative survival from re-hospitalization at 12 months was 64,4% (95%-CI, 31.3-97.5) for MS and 58.7% (95%-CI, 22.2-95.2) for MS-not-treated subjects. No significant difference in survival rate emerged (hazard ratio, 0.04; Log-rank test: p=0.846).

Conclusions: This propensity score-matched study expands on the scant existing evidence of the use and side effects of MS in children and adolescents with AN. These results should be assessed in wider longitudinal samples.

背景:关于情绪稳定剂(MS)在儿童和青少年神经性厌食症(AN)患者中的应用的现有文献大多局限于小案例研究。方法:这是一项观察性的、自然的、倾向评分匹配的研究。接受MS治疗和未接受MS治疗的受试者通过年龄、性别、同时服用非典型抗精神病药物和同时服用抗抑郁药物的倾向评分进行比较。采用症状检查表-90- r、贝克抑郁量表- ii、饮食失调量表-3和身体不安测试- a对一般和特异性精神病理进行评估。评估两组患者入院-出院改变(身体质量指数(BMI)、精神病理)的潜在差异。最后,用Kaplan-Meier分析评估1年后再次住院的情况。结果:研究纳入234例住院患者(15.9+/-3.3年;26, 11.1%接受MS)。倾向评分匹配后,纳入26名MS患者与26名MS未治疗的受试者。MS的平均使用时间为126.1(+/-87.3)天,记录了2例副作用(服用丙戊酸后脱发和嗜睡)。接受ms治疗的患者和未接受ms治疗的患者在入院-出院时BMI和an特异性或一般精神病理的改善方面没有显著差异。多发性硬化症患者12个月再住院后的累积生存率为61.4% (95%-CI, 31.3-97.5),多发性硬化症未治疗组为58.7% (95%-CI, 22.2-95.2)。生存率无显著差异(风险比,0.04;Log-rank检验:p=0.846)。结论:这项倾向评分匹配的研究扩展了MS在AN患儿和青少年中的使用和副作用的现有证据。这些结果应该在更广泛的纵向样本中进行评估。
{"title":"The Role of Mood Stabilizers in Children and Adolescents with Anorexia Nervosa: A 1-year Follow-Up, Propensity Score-Matched Study.","authors":"Jacopo Pruccoli,&nbsp;Antonia Parmeggiani","doi":"10.1055/a-2018-4946","DOIUrl":"https://doi.org/10.1055/a-2018-4946","url":null,"abstract":"<p><strong>Background: </strong>The existing literature on the use of mood stabilizers (MS) in children and adolescents with anorexia nervosa (AN) is limited, for the most part, to small case studies.</p><p><strong>Methods: </strong>This was an observational, naturalistic, propensity score-matched study. Subjects treated and not-treated with MS were compared by being matched via propensity score on age, sex, concurrent atypical antipsychotics, and concurrent antidepressants. General and AN-specific psychopathology was assessed with Symptom Check List-90-R, Beck Depression Inventory-II, Eating Disorders Inventory-3, and Body Uneasiness Test-A. Potential differences in admission-discharge modifications (body mass index (BMI), psychopathology) among the two groups were assessed. Finally, re-hospitalizations after 1-year follow-up were assessed with Kaplan-Meier analyses.</p><p><strong>Results: </strong>The study enrolled 234 hospitalized patients (15.9+/-3.3 years; 26, 11.1% receiving MS). After propensity-score matching, 26 MS patients matched with 26 MS-not-treated subjects were included. MS were used for a mean of 126.1 (+/-87.3) days, and two cases of side effects were documented (alopecia and somnolence with valproate). No significant difference between MS-treated and not-treated patients emerged concerning admission-discharge improvements in BMI and AN-specific or general psychopathology. The cumulative survival from re-hospitalization at 12 months was 64,4% (95%-CI, 31.3-97.5) for MS and 58.7% (95%-CI, 22.2-95.2) for MS-not-treated subjects. No significant difference in survival rate emerged (hazard ratio, 0.04; Log-rank test: p=0.846).</p><p><strong>Conclusions: </strong>This propensity score-matched study expands on the scant existing evidence of the use and side effects of MS in children and adolescents with AN. These results should be assessed in wider longitudinal samples.</p>","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":"56 3","pages":"118-125"},"PeriodicalIF":4.3,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9476730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Synchronization of Fibroblasts Ex Vivo in Psychopharmacology. 体外成纤维细胞同步的精神药理学研究。
IF 4.3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-05-01 DOI: 10.1055/a-1151-4947
Frank Faltraco, Adriana Uzoni, Liliia Shevchuk, Johannes Thome, Denise Palm

The central oscillator for the inner clock is the suprachiasmatic nuclei of the hypothalamus. Furthermore, many peripheral oscillators are present in tissues such as skin. Human derived fibroblasts provide an advantageous model to study circadian rhythmicity as well as the influence of pharmacological drugs on circadian gene expression. Importantly, the synchronization of the circadian system of fibroblasts can be done by different methods. The review presents an overview of the current knowledge of different synchronization methods mostly used in mice or rat fibroblasts. Furthermore, the review sums up and discusses the role of norepinephrine as a possible synchronizer agent.

内部时钟的中央振荡器是下丘脑的视交叉上核。此外,许多外周振荡存在于皮肤等组织中。人源性成纤维细胞为研究昼夜节律以及药物对昼夜节律基因表达的影响提供了有利的模型。重要的是,成纤维细胞昼夜节律系统的同步可以通过不同的方法来完成。本文综述了目前主要用于小鼠或大鼠成纤维细胞的不同同步方法。此外,本文还对去甲肾上腺素作为一种可能的同步剂的作用进行了总结和讨论。
{"title":"Synchronization of Fibroblasts Ex Vivo in Psychopharmacology.","authors":"Frank Faltraco,&nbsp;Adriana Uzoni,&nbsp;Liliia Shevchuk,&nbsp;Johannes Thome,&nbsp;Denise Palm","doi":"10.1055/a-1151-4947","DOIUrl":"https://doi.org/10.1055/a-1151-4947","url":null,"abstract":"<p><p>The central oscillator for the inner clock is the suprachiasmatic nuclei of the hypothalamus. Furthermore, many peripheral oscillators are present in tissues such as skin. Human derived fibroblasts provide an advantageous model to study circadian rhythmicity as well as the influence of pharmacological drugs on circadian gene expression. Importantly, the synchronization of the circadian system of fibroblasts can be done by different methods. The review presents an overview of the current knowledge of different synchronization methods mostly used in mice or rat fibroblasts. Furthermore, the review sums up and discusses the role of norepinephrine as a possible synchronizer agent.</p>","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":"56 3","pages":"101-107"},"PeriodicalIF":4.3,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1055/a-1151-4947","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9473356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
期刊
Pharmacopsychiatry
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1